Duration of objective responses for patients with indolent non-Hodgkin lymphoma discontinuing treatment before progression: Analysis from the phase III CHRONOS-3 trial comparing copanlisib plus rituximab with placebo plus rituximab Meeting Abstract
| Authors: | Matasar, M. J.; Capra, M.; Özcan, M.; Lv, F.; Li, W.; Yañez, E.; Sapunarova, K.; Lin, T.; Jin, J.; Jurczak, W.; Hamed, A.; Wang, M. C.; Soler, L. M.; Cao, A.; Hiemeyer, F.; Childs, B. H.; Shi, Y.; Zinzani, P. L. L. |
| Abstract Title: | Duration of objective responses for patients with indolent non-Hodgkin lymphoma discontinuing treatment before progression: Analysis from the phase III CHRONOS-3 trial comparing copanlisib plus rituximab with placebo plus rituximab |
| Meeting Title: | 63rd Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 138 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2021 Dec 11-14 |
| Meeting Location: | Atlanta, GA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2021-11-23 |
| Language: | English |
| ACCESSION: | WOS:000736413906105 |
| DOI: | 10.1182/blood-2021-150873 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 3538 -- Hybrid meeting, also took place online -- Source: Wos |
